Ann: Mesoblast 2023 Full Year Financial Results Webcast, page-2

MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST

Melbourne, Australia; August 29, and New York, USA; August 29, 2023: Mesoblast Limited(ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases,will host a webcast to discuss operational highlights and financial results for the fourth quarter and fullyear ended June 30, 2023.

The webcast will begin at 8.30am AEST, Thursday, August 31; 6.30pm EDT, Wednesday, August 30,2023. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2023/

The archived webcast will be available on the Investor page of the Company’s website:

www.mesoblast.com

About Mesoblast

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatmentof severe and life-threatening inflammatory conditions. The Company has leveraged its proprietarymesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stageproduct candidates which respond to severe inflammation by releasing anti-inflammatory factors thatcounter and modulate multiple effector arms of the immune system, resulting in significant reductionof the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extendingthrough to at least 2041 in all major markets. The Company’s proprietary manufacturing processesyield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, withdefined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast is developing product candidates for distinct indications based on its remestemcel-L andrexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed forinflammatory diseases in children and adults including steroid refractory acute graft versus hostdisease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome.Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Twoproducts have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Companyhas established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the AustralianSecurities Exchange (MSB) and on the Nasdaq (MESO). For more information, please seewww.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors

Paul Hughes
T: +61 3 9639 6036
E: [email protected]

Media

BlueDot Media
Steve Dabkowski
T: +61 419 880 486
E: [email protected]